Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00292136 · ClinicalTrials.gov registry record

Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study

A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
230
Enrollment target

NCT00292136: Completed study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00292136 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 230 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00292136 has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
230 participants
Enrollment target

Study Summary

Background: * The treatment of addiction often hinges on preventing relapse into drug-using behaviors, which occurs at high rates even after prolonged abstinence. Research has shown that constant reporting through personal data-collection devices, such as electronic diaries, can help prevent relapse and reinforce abstinence. This constant reporting is known as Ecological Momentary Assessment (EMA). * The researchers here at NIDA have already completed two major arms of the study, focusing on patterns of craving and drug use during methadone maintenance, and on whether electronic diaries could help remind outpatients to complete treatment tasks. An ongoing arm of the study is examining connections among drug craving/use, stress, and geographical location. Objective: \- To investigate the role of stress associated with geographical location in drug craving and use. Eligibility: \- Individuals between 18 and 65 years of age or older who are dependent on opioids (cocaine and/or heroin). Design: * The study will last 28 weeks. After the initial screening, participants will receive daily methadone and weekly drug counseling sessions that will continue throughout the study. * After 3 weeks of methadone treatment, participants will have 15 weeks of EMA in which they will record both event-triggered cravings and daily responses (3 per day). EMA will consist of event-triggered recordings (initiated by participants whenever they use heroin or cocaine, or whenever they feel an urge to do so) and random-signal-triggered recordings (3 per day). During EMA, participants will begin a voucher-based program to encourage abstinence from heroin and cocaine. * Participants will also carry global positioning system (GPS) units to record their locations during these 15 weeks, and will complete questionnaires about stress levels at specific intervals during the study. * At the end of the study, participants will have the choice of transferring to a community clinic or undergoing an

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2003-08-15
Est. Completion 2013-06-11

What the finished NCT00292136 record still lists

NCT00292136 is an observational study that tracks outcomes without assigning an intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00292136 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00292136 about?

NCT00292136 is a clinical study titled "Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study". Background: * The treatment of addiction often hinges on preventing relapse into drug-using behaviors, which occurs at high rates even after prolonged abstinence. Research has shown that constant reporting through personal data-collection devices, such as electronic diaries, can help prevent relaps...

What is the current status of trial NCT00292136?

This trial is currently completed. The enrollment target is 230 participants. The study started on 2003-08-15. Estimated completion is 2013-06-11.

Who is sponsoring clinical trial NCT00292136?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00292136, the US trial registry maintained by the National Library of Medicine. NCT00292136 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.